BioPartnering North America

BioPartnering North America

December 11, 2007 11:43 ET

Early Registration Rate for BioPartnering North America Ends January 2, 2008

Register Now and Save!

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 11, 2007) - Technology Vision Group LLC (TVG) continues to offer its early registration rate for the 6th Annual BioPartnering North America conference (BPN). The conference, to be held in Vancouver, B.C., Canada, on February 3-5, 2008, will end its special early rate on January 2, 2008.

Register now for BPN and save 20%.

Register at:

Pharmaceutical companies may also be eligible to receive two registrations for the price of one. Please contact for details.

Sponsored annually by leading life science associations LifeSciences British Columbia, BIOTECanada, and BioAlberta, BPN is one of the world's most prominent life sciences partnering conferences. Over 900 attendees from over 400 international companies based in over 30 countries will converge to meet, network and partner. Attendees range from the world's leading international biotechnology and pharmaceutical firms to smaller, emerging companies; all attend to take advantage of the unique networking opportunities provided at BPN.

"The North American BioPartnering conference provided an efficient and effective means to establish one-on-one meetings with potential collaborators in our field," noted Michael Wanner of Abeome Corp., an Athens, Georgia based biotechnology company developing new screening processes for monoclonal antibodies. "The conference drew key players from big pharma and biotech and allowed small biotech companies the opportunity to explore deals and license agreements."

Two types of presenting company formats are offered, each focused on different stages of development and partnering goals. Emerging Company presentations are tailored to early-stage companies founded no later than 2005. Presenters make a 14-minute podium presentation in the main plenary hall and have further opportunities to meet and discuss in a break out room afterwards. Open House presentations take place in a dedicated booth where companies can meet with potential partners and also have the chance to give a 10-minute presentation in the main plenary hall.

Presenting opportunities are nearly full; please contact Lila Taylor at for further details.

Automated One-to-One Meetings in provides the advantage of automated meeting scheduling, along with the ability to prospect attendees, and manage your time and agenda. For more information on how can optimize your experience at BPN, visit

For more information regarding the BioPartnering North America conference, please visit: http://www.techvision.come/bpn

Conference Sponsors

Platinum Sponsors

Angiotech, AstraZeneca, and Province of British Columbia

Gold Sponsors

Burrill & Company, Cooley Godward Kronish LLP, Ferghana Partners Group, Morrison & Foerster, Wilson Sonsini Goodrich & Rosati, and Wyeth

Silver Sponsors

Crucell, Farris, Vaughan, Wills & Murphy LLP, Italian Trade Commission, Merck & Co., Inc., Novartis, Pfizer Inc., PricewaterhouseCoopers, Procter & Gamble Pharmaceuticals, Roche, Seed Intellectual Property Law Group PLLC, and UK Trade & Investment

Conference Sponsors

Anapharm, BC Innovation Council, Genome British Columbia, Marsh Canada Ltd, and VWR International

Conference & Media Supporters

BIA, Bio Business, BioCentury, Biotechnology Focus, BioWorld Today, Citigate Dewe Rogerson, Contact Canada, European Biopharmaceutical Review, MarketWire, Nature Publishing Group, and Washington Biotechnology & Biomedical Association

2008 Presenting Companies

Akebia Therapeutics, Alfama Inc., Alphora Research Inc., Ambit Biosciences, Apthera, Inc., Aquinox Pharmaceuticals Inc., Aska Research, Auxilium, Inc., Benitec, Biolex Therapeutics, BioMarck Pharmaceuticals, Ltd., Burnham Institute for Medical Research, Calibrant Biosystems, Inc, Cequent Pharmaceuticals, CIRION BioPharma Research Inc., ConjuChem Inc., Cook Pharmica LLC, Critical Outcome Technologies, Curalogic A/S, Cytochroma Inc., Cytokinetics, Inc., deCODE Genetics, Inc., Epidauros Biotechnologie AG (A Division of Clinical Data), Eurand International S.p.A., Evotec (UK) Limited, Fresenius AG, Ichor Medical Systems, Inc., ImmunoVaccine Technologies Inc., Inimex Pharmaceuticals, Inc., InNexus Biotechnology Inc., Inovio Biomedical Corp., Inverseon, Inc., IRX Therapeutics, Inc., Kane Biotech Inc., Laureate Pharma, Inc, Nektar Therapeutics, Nerites Corporation, NeuroProtect, Inc., NPIL Pharma Torcan, Office of Biomedical Advanced Research and Development Authority (BARDA), OxThera, Patheon Inc., Perceptronix Medical, Inc., Pharmaceutical Profiles Ltd., Pharmatek Laboratories, Inc., Pharmexa-Epimmune, Plexera Corporation, Presidio Pharmaceuticals, ProCell Therapeutics, Inc./Chonnam National, ProtAffin Biotechnologie AG, Quest PharmaTech Inc, Regeron, Inc, Ribomed Biotechnologies, Inc, Sapphire Therapeutics, Scimega Research Inc., Sensific Technologies Inc., Sidec Technologies AB, Silence Therapeutics AG, Sloning BioTechnology, Stem Cell Therapeutics Corp., SuperGen Inc., Syntaxin Ltd, Thallion Pharmaceuticals, The Hungarian Investment and Trade Development Agency (ITD Hungary), The Vaccines Company, Tripos Inc., TriStar Technology Group, LLC. , Urodynamix Technologies Ltd., VentiRx, VM Discovery, Inc., Vyteris, Welichem Biotech Inc., XOMA Ltd., YM BioSciences Inc.

Contact Information